ReviewRedox report : communications in free radical research2026
From ER and mitochondria to contact sites: integrated regulation of ferroptosis in cardiovascular diseases.
Review in Redox report : communications in free radical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Iron is a central regulator of cellular redox homeostasis, supporting essential physiological processes. Given its critical biological importance, iron homeostasis is tightly regulated at both the systemic and cellular levels. Ferroptosis is a metabolically regulated, iron-dependent form of cell death characterized by the accumulation of phospholipid hydroperoxides driven by iron-catalyzed redox reactions, ultimately leading to oxidative membrane damage. Accumulating evidence indicates that ferroptosis emerges from the coordinated activity of multiple subcellular organelles rather than from isolated pathways. In this context, the endoplasmic reticulum (ER) and mitochondria have recently been established as key regulators of ferroptotic signaling. Notably, mitochondria-associated membranes (MAMs), by spatially coordinating redox signaling and lipid peroxidation, calcium fluxes, mitochondrial metabolism and lipid remodeling, are increasingly recognized as central hubs within the ferroptotic cascade, acting as modulators of cellular susceptibility to ferroptosis and as key sites of its execution. Owing to its strong dependence on mitochondrial oxidative phosphorylation, the heart is particularly sensitive to perturbations in iron homeostasis. Notably, growing evidence supports a pathogenic role for ferroptosis in cardiovascular diseases (CVDs), linking iron-dependent oxidative stress to cardiomyocyte dysfunction and tissue injury. Accordingly, ferroptosis has emerged as a potential therapeutic target in cardiovascular pathology. This review examines how ER and mitochondrial dysfunction contribute to ferroptotic signaling in CVDs and discusses the hypothesis that MAMs may function as central regulatory interfaces coordinating these processes. Elucidating these mechanisms is essential for the development of novel therapeutic strategies aimed at modulating ferroptosis and limiting CVDs progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.